Gamida Cell Ltd.

    Gamida Cell Ltd.

    NNASDAQ:GMDA
    - -
    USD
    - -
    - -
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    0.02
    Basic EPS, GAAP
    -1.26
    -1.06
    -10.53
    -1.17
    -1.41
    -1.52
    -1.24
    - -
    -0.49
    Free Cash Flow per Basic Share
    -0.72
    -0.94
    -5.59
    -1.39
    -1.42
    -1.63
    -1.2
    - -
    -0.63
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -5.41
    -6.47
    -33.66
    -6.91
    -5.66
    -5.69
    -6.53
    - -
    -3.94
    Tangible Book Value per Share
    0.61
    1.28
    4.91
    1.19
    2.95
    0.74
    -0.13
    - -
    -0.15
    Basic Weighted Avg Shares
    18
    18
    5
    29
    44
    59
    64
    - -
    127
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    2
    3
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -4,071.92
    -2,924.42
    Depreciation Expense
    - -
    - -
    - -
    2
    - -
    - -
    - -
    2
    3
    Net Income, GAAP
    -23
    -19
    -53
    -34
    -62
    -90
    -79
    -63
    -62
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -3,531.17
    -2,317.95
    Working Capital
    17
    39
    55
    45
    109
    73
    42
    29
    -61
    LT Debt
    - -
    - -
    - -
    4
    6
    77
    101
    75
    2
    Total Equity
    11
    23
    25
    35
    129
    44
    -8
    -3
    -19
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    ST Debt
    1
    8
    76
    LT Borrowings
    81
    73
    - -
    LT Finance Leases
    2
    2
    2
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    132
    144
    154
    Market Capitalization
    104
    42
    5

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    Total Current Assets
    69
    55
    33
    Cash, Cash Equivalents & STI
    60
    47
    25
    Accounts Receivable, Net
    1
    2
    1
    Inventories
    2
    2
    2
    Total Current Liabilities
    21
    25
    95
    Payables & Accruals
    19
    17
    18
    ST Debt
    1
    8
    76
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    12.54%
    -63.24%
    Free Cash Flow
    - -
    27.44%
    4.46%
    Net Income, GAAP
    - -
    11.55%
    -20.63%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    1
    1
    2
    2024
    1
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.34
    -0.31
    -0.29
    - -
    -1.24
    2023
    -0.27
    -0.31
    -0.01
    - -
    - -
    2024
    -0.13
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with Omidubicel

    • globenewswire.com

      On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

    • businesswire.com

      Gamida Cell Announces New Leadership Under Ownership of Highbridge Capital Management

    • investorplace.com

      Why Is Gamida Cell (GMDA) Stock Down 82% Today?

    • seekingalpha.com

      Gamida Cell Ltd. (GMDA) Q4 2023 Earnings Call Transcript

    • globenewswire.com

      Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management

    • globenewswire.com

      Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update

    • globenewswire.com

      Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

    • globenewswire.com

      Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

    • globenewswire.com

      Gamida Cell Actively Pursuing Strategic Alternatives

    • globenewswire.com

      Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

    • globenewswire.com

      Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

    • globenewswire.com

      Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

    • seekingalpha.com

      Gamida Cell Ltd. (GMDA) Q3 2023 Earnings Call Transcript

    • globenewswire.com

      Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

    • globenewswire.com

      Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

    • globenewswire.com

      Gamida Cell to Report Third Quarter 2023 Financial Results

    • businesswire.com

      Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201

    • businesswire.com

      Gamida Cell Issues Update on Israel Operations

    • marketwatch.com

      These Israeli pharmaceutical stocks are down in the wake of Hamas attack